Javaeed Arslaan, Ghauri Sanniya Khan
Department of Pathology, Poonch Medical College, Azad Kashmir, Rawalakot 1235, Pakistan.
Department of Emergency Medicine, Shifa International Hospital, Islamabad, 44000, Pakistan.
World J Clin Oncol. 2019 Jun 24;10(6):234-246. doi: 10.5306/wjco.v10.i6.234.
SOX2 is a regulator of pluripotent cellular transcription, yet it has been recently integrated in cancer biology. The present study provides an analytic insight into the correlation of SOX2 overexpression with cancer metastasis and patient survival.
To investigate the association of SOX2 overexpression with metastasis and its implication in the prognosis of cancer patients.
A meta-analysis was conducted including studies that compared the association of low or high SOX2 expression with lymph node metastasis (LNM) and/or distant metastasis (DM). The following data were additionally extracted: survival, including the overall survival (OS) and disease-free survival (DFS), and prevalence of high and low SOX2 expression. Odds ratios (commonly known as ORs) and their respective 95% confidence intervals (CIs) were used to investigate the association between SOX2 expression and LNM and DM, while hazard ratios (commonly known as HRs) and 95%CIs were applied to evaluate the prognostic markers.
In a total of 2643 patients (60.88% males), the pooled prevalence of SOX2 overexpression was 46.22% (95%CI: 39.07%-53.38%) in different types of cancer. SOX2 overexpression significantly correlated with DM (OR = 1.79, 95%CI: 1.20-3.25, < 0.008) compared to low SOX2 expression. In subgroups analyses, a high SOX2 expression was associated with LNM in cancers of the lung, breast, and colon and associated with DM in hepatic, head and neck, and colon cancers. SOX2 overexpression was also associated with a shorter OS (HR = 1.65, 95%CI: 1.34-2.04, < 0.001) and DFS (HR = 1.54, 95%CI: 1.14-2.08, = 0.005).
A remarkable role of SOX2 overexpression was observed in cancer biology and metastasis. However, many questions in the regulatory pathways need to be addressed to reveal as many functional aspects as possible to tailor new targeted therapeutic strategies.
SOX2是多能细胞转录的调节因子，但最近已被纳入癌症生物学研究。本研究对SOX2过表达与癌症转移及患者生存之间的相关性进行了分析洞察。
探讨SOX2过表达与转移的关联及其在癌症患者预后中的意义。
进行了一项荟萃分析，纳入了比较SOX2低表达或高表达与淋巴结转移（LNM）和/或远处转移（DM）之间关联的研究。另外提取了以下数据：生存情况，包括总生存期（OS）和无病生存期（DFS），以及SOX2高表达和低表达的发生率。比值比（通常称为OR）及其各自的95%置信区间（CI）用于研究SOX2表达与LNM和DM之间的关联，而风险比（通常称为HR）和95%CI用于评估预后标志物。
在总共2643例患者（男性占60.88%）中，不同类型癌症中SOX2过表达的合并发生率为46.22%（95%CI：39.07%-53.38%）。与SOX2低表达相比，SOX2过表达与DM显著相关（OR = 1.79，95%CI：1.20-3.25，P < 0.008）。在亚组分析中，SOX2高表达与肺癌、乳腺癌和结肠癌的LNM相关，与肝癌、头颈癌和结肠癌的DM相关。SOX2过表达还与较短的OS（HR = 1.65，95%CI：1.34-2.04，P < 0.001）和DFS（HR = 1.54，95%CI：1.14-2.08，P = 0.005）相关。
观察到SOX2过表达在癌症生物学和转移中具有显著作用。然而，调控途径中的许多问题需要解决，以揭示尽可能多的功能方面，从而制定新的靶向治疗策略。
